
Jawahar Lal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1375386/publications.pdf Version: 2024-02-01



ΙΛΥΛΗΛΡΙΑΙ

#	Article	IF	CITATIONS
1	Dried blood spots: Concepts, present status, and future perspectives in bioanalysis. Drug Testing and Analysis, 2014, 6, 399-414.	1.6	124
2	Discovery of a New Class of Natural Product-Inspired Quinazolinone Hybrid as Potent Antileishmanial agents. Journal of Medicinal Chemistry, 2013, 56, 4374-4392.	2.9	120
3	A combination of complexation and self-nanoemulsifying drug delivery system for enhancing oral bioavailability and anticancer efficacy of curcumin. Drug Development and Industrial Pharmacy, 2017, 43, 847-861.	0.9	62
4	Clinical pharmacokinetics and interaction of centchroman — A mini review. Contraception, 2010, 81, 275-280.	0.8	53
5	Role of enterohepatic recirculation in drug disposition: cooperation and complications. Drug Metabolism Reviews, 2016, 48, 281-327.	1.5	45
6	PEGylated chitosan nanoparticles potentiate repurposing of ormeloxifene in breast cancer therapy. Nanomedicine, 2016, 11, 2147-2169.	1.7	29
7	Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on "humanized―animal models. Drug Metabolism Reviews, 2014, 46, 475-493.	1.5	28
8	An insight into tetrahydro-β-carboline–tetrazole hybrids: synthesis and bioevaluation as potent antileishmanial agents. MedChemComm, 2017, 8, 1824-1834.	3.5	25
9	Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin. Drug Testing and Analysis, 2017, 9, 1124-1136.	1.6	25
10	Simultaneous liquid chromatographic determination of centchroman and its 7-demethylated metabolite in serum and milk. Biomedical Applications, 1994, 658, 193-197.	1.7	19
11	Gender-related pharmacokinetics and bioavailability of a novel anticancer chalcone, cardamonin, in rats determined by liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 986-987, 23-30.	1.2	14
12	Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Contraception, 2006, 74, 165-173.	0.8	8
13	Simultaneous quantification of centchroman and its 7â€demethylated metabolite in rat dried blood spot samples using LCâ€MS/MS. Biomedical Chromatography, 2012, 26, 1089-1095.	0.8	8
14	Rapid quantitative analysis of ormeloxifene and its active metabolite, 7-desmethyl ormeloxifene, in rat plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 997, 7-15.	1.2	4
15	HPLC–MS-MS Method Development and Validation of Antileishmanial Agent, S010-0269, in Hamster Serum. Journal of Chromatographic Science, 2015, 53, 1542-1548.	0.7	3
16	Insights into the pharmacokinetic properties of antitubercular drugs. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 765-778.	1.5	3
17	PK–PD interaction study of angiotensin II antagonist, losartan, with selective estrogen receptor modulator, centchroman. International Journal of Pharmacokinetics, 2016, 1, 17-23.	0.5	1
18	Coadministration of HMG-CoA reductase inhibitors, atorvastatin and rosuvastatin, does not affect contraceptive efficacy of centchroman. European Journal of Contraception and Reproductive Health Care, 2015, 20, 231-235.	0.6	0

#	Article	IF	CITATIONS
19	Model based population PK-PD analysis of furosemide for BP lowering effect: A comparative study in primary and secondary hypertension. European Journal of Pharmaceutical Sciences, 2017, 109, 253-261.	1.9	Ο
20	Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 971-976.	1.4	0
21	Liquid chromatography–tandem mass spectrometry method for the quantification of a potent H3 receptor antagonist conessine in serum and its application to pharmacokinetic studies. European Journal of Mass Spectrometry, 2018, 24, 289-298.	0.5	ο